MDM2抑制剂米拉德美坦在MDM2扩增内膜肉瘤中的临床活性及探索性耐药机制:一项开放标签Ib/II期研究
本研究为日本全国罕见癌登记研究子研究,纳入MDM2扩增且TP53野生型内膜肉瘤患者,米拉德美坦260 mg口服每14天连用3天、28天为一周期。11例入组、10例可评估疗效,2例(20%)持久缓解超过15个月;抗肿瘤活性与TWIST1扩增相关(P=0.028),与CDKN2A缺失负相关(P=0.071)。系列液体活检检出获得性TP53突变,为探索性耐药机制。
要点
- 米拉德美坦260 mg口服每14天连用3天、28天为一周期,用于MDM2扩增且TP53野生型内膜肉瘤。
- 10例可评估患者中2例(20%)持久缓解超过15个月。
- 抗肿瘤活性与TWIST1扩增相关(P=0.028),与CDKN2A缺失负相关(P=0.071)。
核心结论
- 米拉德美坦可能成为MDM2扩增内膜肉瘤的潜在治疗策略。
- 系列液体活检检出获得性TP53突变,为米拉德美坦的探索性耐药机制。
研究设计与样本
- 开放标签Ib/II期研究,作为日本全国罕见癌登记研究的一个子研究。
- 入组MDM2扩增、TP53野生型内膜肉瘤患者,共11例入组,其中10例纳入疗效分析。
- 米拉德美坦260 mg口服每日一次,每14天连用3天,28天为一周期共用两次。
主要发现
- 10例疗效分析患者中2例(20%)出现持续超过15个月的持久缓解。
- 抗肿瘤活性与TWIST1扩增相关(P=0.028),与CDKN2A缺失呈负相关(P=0.071)。
- 系列液体活检中检出获得性TP53突变,为米拉德美坦的探索性耐药机制。
临床怎么用
- 作者认为米拉德美坦可能成为内膜肉瘤的潜在治疗策略。
- 作者提出优化结局的策略可包括使用新生物标志物(TWIST1扩增和CDKN2A缺失)筛选可能从米拉德美坦获益的MDM2扩增内膜肉瘤患者,并与其他靶向治疗联合。
- 作者提出TP53系列液体活检可用于评估米拉德美坦治疗期间的疾病状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Intimal sarcoma is an extremely rare, life-threatening malignant neoplasm. Murine double minute 2 (MDM2) amplification is observed in >70% of intimal sarcomas. Milademetan, an MDM2 inhibitor, may provide clinical benefit in this patient population. We conducted a phase Ib/II study in patients with MDM2-amplified, wild-type TP53 intimal sarcoma as a substudy of a large nationwide registry for rare cancers in Japan. Milademetan (260 mg) was administered orally once daily for 3 days every 14 days, twice in a 28-day cycle. Of 11 patients enrolled, 10 were included in the efficacy analysis. Two patients (20%) showed durable responses for >15 months. Antitumor activity correlated with TWIST1 amplification (P = 0.028) and negatively with CDKN2A loss (P = 0.071). Acquired TP53 mutations were detected in sequential liquid biopsies as a novel exploratory resistance mechanism to milademetan. These results suggest that milademetan could be a potential therapeutic strategy for intimal sarcoma. SIGNIFICANCE: Strategies to optimize outcomes could include the use of new biomarkers (TWIST1 amplification and CDKN2A loss) to select patients with MDM2-amplified intimal sarcoma who might benefit from milademetan and combination with other targeted treatments. Sequential liquid biopsy of TP53 can be used to evaluate disease status during treatment with milademetan. See related commentary by Italiano, p. 1765. This article is highlighted in the In This Issue feature, p. 1749.
引用
- Koyama T, Shimizu T, Kojima Y, et al. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study. Cancer Discov. 2023. PMID: 37369013. doi:10.1158/2159-8290.CD-23-0419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。